16 May 2024 | Thursday | News
Picture Courtesy | Public Domain
OmniAb, Inc. announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today the Company presented an overview of xPloration, a high-throughput single B-cell screening platform that leverages machine learning and Artificial Intelligence (AI), in a presentation titled “Deep Screening in Harmony with Artificial Intelligence for Bispecific Antibody Discovery.”
“xPloration enables large-scale data collection of massive, diverse antibody repertoires generated utilizing the Biological Intelligence™ built into our proprietary engineered animals, and facilitates efficient evaluation of AI selections from these repertoires,” said Bob Chen, Ph.D., Senior Director, Discovery Systems. “The synergy between xPloration, OmniFlic, OmniClic, and OmniDeep enables new bispecific antibody discovery workflows for our partners. We are delighted that our innovative technology stack continues to make important impacts on partner R&D pipelines, and assists in delivering novel, highly effective therapeutic solutions to patients.”
Today’s presentation included a case study demonstrating the ability to rapidly discover antibody panels from the Company’s OmniFlic and OmniClic platforms against a promising target called NKp46. These antibodies may be used by partners in a natural killer cell engager bispecific antibody. With xPloration, OmniAb’s scientific team screened tens of millions of cells and recovered thousands of unique antibody sequences. The team applied OmniDeep to help understand natural immune repertoires and to guide antibody selection and characterization, resulting in a large panel of high-affinity, potentially developable antibodies.
© 2024 Biopharma Boardroom. All Rights Reserved.